2,3,4-substituted cyclopentanones as therapeutic agents

A liquid comprising a compound, wherein said liquid is pharmaceutically acceptable, said compound comprising

• or a pharmaceutically acceptable salt or a prodrug thereof;
• wherein
• a dashed line represents the presence or absence of a bond;
• Y is a carboxylic acid, sulfonic acid, or phosphonic acid functional group;
• or an amide or ester thereof comprising from 0 to 12 carbon atoms;
• or Y is hydroxymethyl or an ether thereof comprising from 0 to 12 carbon atoms;
• or Y is a tetrazolyl functional group;
• A is —(CH2)qG(CH2)rG(CH2)s—, wherein G is S or O, r is at least 2, and wherein q+r+s=4;
• B is hydrogen, CN, CO2H, C1-6 hydrocarbyl, or —(CH2)mX(CH2)pH, wherein m is at least 1 and the sum of m and p is from 1 to 5;
• X is S or O;
• J is H, CH3, or CF3;
• and
• E is a moiety comprising a covalently bonded chain of from 2 to 13 atoms.

A method comprising administering a compound to a mammal for the treatment of glaucoma or ocular hypertension, said compound comprising

• or a pharmaceutically acceptable salt or a prodrug thereof;
• wherein
• a dashed line represents the presence or absence of a bond;
• Y is a carboxylic acid, sulfonic acid, or phosphonic acid functional group;
• or an amide or ester thereof comprising from 0 to 12 carbon atoms;
• or Y is hydroxymethyl or an ether thereof comprising from 0 to 12 carbon atoms;
• or Y is a tetrazolyl functional group;
• A is —(CH2)qG(CH2)rG(CH2)s—, wherein G is S or O, r is at least 2, and wherein q+r+s=4;
• B is hydrogen, CN, CO2H, C1-6 hydrocarbyl, or —(CH2)mX(CH2)pH, wherein m is at least 1 and the sum of m and p is from 1 to 5;
• X is S or O;
• J is H, CH3, or CF3;
• and
• E is a moiety comprising a covalently bonded chain of from 2 to 13 atoms.

A pharmaceutical product, comprising a container adapted to dispense a compound in an ophthalmic liquid from said container in metered form;

• said compound comprising
• or a pharmaceutically acceptable salt or a prodrug thereof;
• wherein
• a dashed line represents the presence or absence of a bond;
• Y is a carboxylic acid, sulfonic acid, or phosphonic acid functional group;
• or an amide or ester thereof comprising from 0 to 12 carbon atoms;
• or Y is hydroxymethyl or an ether thereof comprising from 0 to 12 carbon atoms;
• or Y is a tetrazolyl functional group;
• A is —(CH2)qG(CH2)rG(CH2)s—, wherein G is S or O, r is at least 2, and wherein q+r+s=4;
• B is hydrogen, CN, CO2H, C1-6 hydrocarbyl, or —(CH2)mX(CH2)pH, wherein m is at least 1 and the sum of m and p is from 1 to 5;
• X is S or O;
• J is H, CH3, or CF3;
• and
• E is a moiety comprising a covalently bonded chain of from 2 to 13 atoms.

A method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound comprising

• or a pharmaceutically acceptable salt or a prodrug thereof;
• wherein a dashed line represents the presence or absence of a bond;
• Y is a carboxylic acid, sulfonic acid, or phosphonic acid functional group;
• or an amide or ester thereof comprising from 0 to 12 carbon atoms;
• or Y is hydroxymethyl or an ether thereof comprising from 0 to 12 carbon atoms;
• or Y is a tetrazolyl functional group;
• A is —(CH2)qG(CH2)rG(CH2)s—, wherein G is S or O, r is at least 2, and wherein q+r+s=4;
• B is hydrogen, CN, CO2H, C1-6 hydrocarbyl, or —(CH2)mX(CH2)pH, wherein m is at least 1 and the sum of m and p is from 1 to 5;
• X is S or O;
• J is H, CH3, or CF3;
• and
• E is a moiety comprising a covalently bonded chain of from 2 to 13 atoms.